Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | FABP4 | P15090 | 1/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.60 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567367 | 1.00 | MAPT (0.68) | MAPTALOX15MEN1KMT2AFABP4 | |
| Acetonitrile SCHEMBL27301956 | 0.91 | MEN1 (0.59) | MAPTALOX15MEN1KMT2AFABP4 | |
| SCHEMBL25449209 | 0.87 | AKR1C3 (0.66) | MAPTALOX15MEN1KMT2AFABP4 | |
| SCHEMBL8052123 | 0.87 | MEN1 (0.58) | MAPTALOX15MEN1KMT2AFABP4 | |
| SCHEMBL10936401 | 0.87 | MEN1 (0.58) | MAPTALOX15MEN1KMT2AFABP4 | |
| Fenamic Acid SCHEMBL27925717 | 0.86 | FABP4 (0.82) | MAPTALOX15MEN1KMT2AFABP4 | |
| SCHEMBL30567365 | 0.85 | MEN1 (0.56) | MAPTALOX15MEN1KMT2AFABP4 | |
| SCHEMBL7844252 | 0.85 | MEN1 (0.56) | MAPTALOX15MEN1KMT2AFABP4 | |
| SCHEMBL6620978 | 0.85 | AKR1C3 (0.57) | MAPTALOX15MEN1KMT2AFABP4 | |
| SCHEMBL30982117 | 0.85 | AKR1C3 (0.57) | MAPTALOX15MEN1KMT2AFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | HAMAD BIN KHALIFA UNIVERSITY (QA) | 2023-11-30 | — | — | US | disclosed |
| CN-116589406-A | Preparation method of polysubstituted acridine derivative | 深圳职业技术学院 | 2023-08-15 | — | — | CN | disclosed |
| EP-3464317-B1 | AMINOSTEROID DERIVATIVES AND PROCESS FOR PRODUCING SAME | UNIV LAVAL (CA) | 2023-04-26 | — | — | EP | disclosed |
| US-11174282-B2 | Aminosteroid derivatives and process for producing same | UNIVERSITé LAVAL (CA) | 2021-11-16 | — | — | US | disclosed |
| WO-2017205964-A1 | AMINOSTEROID DERIVATIVES AND PROCESS FOR PRODUCING SAME | UNIVERSITé LAVAL (CA) | 2017-12-07 | — | — | WO | disclosed |
| US-8653054-B2 | 2-(N-substituted piperazinyl) steroid derivatives | UNIVERSITE LAVAL (CA) | 2014-02-18 | — | — | US | disclosed |
| US-8653054-B2 | 2-(N-substituted piperazinyl) steroid derivatives | UNIVERSITE LAVAL (CA) | 2014-02-18 | — | — | US | disclosed |
| US-8163906-B2 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2148862-B1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20110312926-A1 | 2-(N-Substituted Piperazinyl) Steroid Derivatives | UNIVERSITE LAVAL (CA) | 2011-12-22 | — | — | US | disclosed |
| WO-2008138920-A1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| US-7378154-B2 | Radiation transparent glass, polycarbonate, polyethylene terephthalate, acrylic, methyl cellulose or polycycloolefin substrate, a fluoropolymer layer containing and a rare earth metal compound, and a low refractive index layer; fluorescence; light amplification; improved efficiency; light emitting diodes | DAIKIN INDUSTRIES, LTD. (JP) | 2008-05-27 | — | — | US | disclosed |
| EP-0783505-B1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 2001-03-07 | — | — | EP | disclosed |
| CN-1046731-C | Pyrrolo [2,3-d ] pyrimidines and their use | NOVARTIS AG (CH) | 1999-11-24 | — | — | CN | disclosed |
| US-5869485-A | Pyrrolo 2,3-d!pyrimidines and their use | NOVARTIS FINANCE CORP. (US) | 1999-02-09 | — | — | US | disclosed |
| CN-1164234-A | Pyrrolo [2, 3-d ] pyrimidines and their use | NOVARTIS AG (CH) | 1997-11-05 | — | — | CN | disclosed |
| EP-0783505-A1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | Novartis AG (CH) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010028-A1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 1996-04-04 | — | — | WO | disclosed |
| US-5153226-A | Administering as anticholesterol agents, for atherosclerosis | WARNER-LAMBERT COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0415413-A1 | Acat inhibitors | WARNER-LAMBERT COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | MAPT, TTR, HTT | MAPT 1/4885ALOX15 1017/4885MEN1 2502/4885 |
| US-20110312926-A1 | 2-(N-Substituted Piperazinyl) Steroid Derivatives | NR5A1, HSD17B11, CYP17A1 | MAPT 4699/4885ALOX15 2932/4885MEN1 3323/4885 |
| US-11174282-B2 | Aminosteroid derivatives and process for producing same | HSD17B11, HSD17B7, CYP19A1 | MAPT 3922/4885ALOX15 1313/4885MEN1 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.